viewAnteris Technologies Ltd

Admedus commences animal trials for heart valve device

The heart valve device could be a game-changer in the US$3.5 billion market.

heart puzzle being dissected with tweezers
The trial will involve multiple animals

Admedus Ltd (ASX:AHZ) has commenced animal trials by completing the first successful live implantation of its unique single-piece aortic heart valve.

This represents a key milestone in the development of its patented transcatheter aortic valve replacement (TAVR) project.

Admedus has partnered with a European lab to examine the safety and feasibility of the unique valve in live sheep.

The first single-piece valve was implanted today officially marking the start of the trial period, which is expected to last for around five months.

READ: Admedus board members stand with shareholders and buy shares

Admedus’s CEO Wayne Paterson said: “Today is a significant step for the TAVR project as we move into the next stage of development.

“It was exciting to observe the first-ever of our unique single-piece valves being placed inside a living heart.

“These experiments are being conducted by global leaders in the field and will provide critical insight for our development team as we accelerate towards product commercialisation.”

READ: Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

Momentum continues to build after recent lab testing of multiple valves were run out to 400 million cycles, which is roughly 10 years of human use.

Whilst the Admedus valves remained functional after 400 million cycles, the competitor valve showed significant fatigue at 250 million cycles.

Paterson added: “This device has the potential to be a game-changer for patients, the Company and the US$3.5 billion TAVR market.”

Quick facts: Anteris Technologies Ltd

Price: 3.75 AUD

Market: ASX
Market Cap: $22.16 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read